Abstract： Objective:To investigate the infection of Helicobacter pylori(Hp)and the changes of inflammatory factors in patients with chronic gastritis after anti-Hp treatment.Methods:A total of 97 patients with chronic gastritis admitted to the Third People′s Hospital of Xantai from December 2017 to December 2020 were selected, including 54 males and 43 females, aged(41.78±5.64)years old, ranging in age from 25 to 63 years old.The patients were randomly divided into monotherapy group( n=48)and combination therapy group( n=49)by random number table method.Patients in the monotherapy group were given pantoprazole sodium enteric-dissolved capsules, and patients in the combined treatment group were given amoxicillin capsules and furazolidone tablets on the basis of monotherapy group.Clinical treatment effect, gastric mucosa score, gastrin level, interleukin-6(IL-6), tumor necrosis factor-α(TNF-α), interleukin-8(IL-8)levels and Hp infection conversion rate were compared between 2 groups. Results:The total effective rate in the combined treatment group[93.9%(46/49)]was higher than that in the monotherapy group[79.2%(38/48)], and the difference was statistically significant( P<0.05). Before treatment, there was no significant difference in gastric mucosa score and gastrin level between 2 groups( P>0.05). After treatment, gastric mucosa score[(1.59±0.26)points, (0.69±0.12)points]and gastrin level[(100.82±9.48)ng/L, (78.42±6.40)ng/L]in 2 groups were lower than those before treatment[(2.36±0.46)points, (2.39±0.44)points]. (132.94±12.65)ng/L, (132.89±12.75)ng/L], and the combination treatment group was lower than the monotherapy group, the difference was statistically significant( P<0.05). Before treatment, there were no significant differences in the levels of IL-6, TNF-α and IL-8 between 2 groups( P>0.05). After treatment, the levels of IL-6[(24.74±2.95)pg/ml, (17.89±2.58)pg/ml], TNF-α[(32.76±4.54)pg/ml, (28.49±3.49)pg/ml], IL-8[(35.94±5.27)pg/ml, (27.48±4.14)pg/ml]were lower than those before treatment[(27.76±3.86)pg/ml, (27.79±3.84)pg/ml, (42.94±5.65)pg/ml, (42.89±5.75)pg/ml, (46.82±5.89)pg/ml, (46.76±5.98)pg/ml], and the combination treatment group was lower than the monotherapy group, the difference was statistically significant( P<0.05). The negative conversion rate of HP infection in the combined treatment group[100%(49/49)]was higher than that in the monotherapy group[77.1%(37/48)], and the difference was statistically significant( P<0.05). Conclusion:The treatment of anti-Helicobacter pylori infection in patients with chronic gastritis can improve the treatment effect, increase the negative conversion rate of Hp infection, reduce the level of serum inflammatory factors, and help to alleviate the clinical symptoms of patients.